<DOC>
	<DOCNO>NCT00117065</DOCNO>
	<brief_summary>The purpose study evaluate Aranesp速 administer subcutaneously ( SC ) maintain hemoglobin ( Hb ) level renal transplant recipient .</brief_summary>
	<brief_title>Study Transplant Related Anemia Treated With Aranesp速 ( STRATA )</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Subjects great 6 month postrenal transplant ( live cadaveric ) Using adequate contraceptive precaution , childbearing potential Available followup assessment dose visit Hb concentration le 11.0 g/dL within 3 month screen hemoglobin concentration le 11.0 screening period Expected initiate dialysis transplantation schedule kidney transplant within 6 month study start , less 1 year life expectancy Systemic hematologic disease , myeloma , hemolytic anemia , malignancy ( exclude basal cell carcinoma ) Active systemic chronic infection Uncontrolled hypertension define diastolic blood pressure great 110 mm Hg 2 separate occasion 2 week prior screen Known hypersensitivity Aranesp速 product 's excipients Disorders compromise ability subject give write informed consent and/or comply study procedure Use erythropoietic protein androgen therapy within 12 week prior screen Females pregnant breastfeed Currently enrol receive treatment investigational drug/device trial within past 30 day Have previously enrol study Recent history ( within 12 week prior screen ) severe cardiovascular event , grand mal seizure , dialysis major surgery Have receive red blood cell transfusion ( ) within 8 week prior screen , currently active bleeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Kidney transplant , Renal transplant</keyword>
	<keyword>Aranesp速 , Darbepoetin alfa</keyword>
	<keyword>Amgen , Q2W dosing , Q4W dose</keyword>
</DOC>